The Delhi High Court has asked the Centre reasons for inviting bids for supply of CGHS medicines from drug manufacturers on the basis of brand names instead of their chemical composition and sought an explanation from the government.
Ajit Mishra, vice president, Research, Religare Broking, answers your stock market queries.
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
